Lantern Pharma, Inc. (LTRN)
1.85
+0.01
(+0.54%)
USD |
NASDAQ |
Sep 09, 11:41
Lantern Pharma Debt to Equity Ratio : -0.0123 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.0123 |
| March 31, 2026 | 0.0172 |
| December 31, 2025 | 0.012 |
| September 30, 2025 | 0.0098 |
| June 30, 2025 | 0.0116 |
| March 31, 2025 | 0.0116 |
| December 31, 2024 | 0.0115 |
| September 30, 2024 | 0.0109 |
| June 30, 2024 | 0.0071 |
| March 31, 2024 | 0.0054 |
| December 31, 2023 | 0.0057 |
| September 30, 2023 | 0.006 |
| June 30, 2023 | 0.0065 |
| Date | Value |
|---|---|
| March 31, 2023 | 0.0049 |
| December 31, 2022 | 0.0009 |
| September 30, 2022 | 0.0016 |
| June 30, 2022 | 0.0021 |
| March 31, 2022 | 0.0026 |
| December 31, 2021 | 0.0029 |
| September 30, 2021 | 0.0032 |
| June 30, 2021 | 0.0035 |
| March 31, 2021 | 0.0013 |
| December 31, 2020 | 0.0055 |
| September 30, 2020 | 0.005 |
| June 30, 2020 | 0.0091 |
| March 31, 2020 | 0.0993 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 2.956 |
| Oncolytics Biotech, Inc. | -0.0726 |
| Sangamo Therapeutics, Inc. | -1.020 |
| Sarepta Therapeutics, Inc. | 0.6845 |
| Anixa Biosciences, Inc. | 0.0127 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 8.602M |
| Total Liabilities (Quarterly) | 11.82M |
| Shareholders Equity (Quarterly) | -3.217M |
| Current Ratio | 1.957 |
| Net Debt Paydown Yield | 0.06% |